marketing authorisation
The Abraxis judgement – CJEU clarifies the scope of Neurim teaching is narrow
By Louise Jonshammar | Posted on March 21, 2019
Article 3d of the SPC-regulation, read in conjunction with Article 1b, must be interpreted as meaning that the marketing authorisation for a new formulation of an old active ingredient cannot be regarded as being the first marketing authorisation for that product, when the active ingredient has already been the subject of a marketing authorisation. The European Court of...
Tags: CJEU, formulation, marketing authorisation, Patent, SPC Regulation
Recent contributors
Partner, European Patent Attorney
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
